Abstract
Immunomodulatory effects of statins in vitro and in experimental models of asthma and COPD could potentially be relevant to the treatment of chronic airway diseases. This article provides an overview of the evidence from the key clinical studies on the effects of statins on clinical outcomes and inflammatory biomarkers in asthma and COPD. Future directions for clinical studies of statins in asthma and COPD are discussed. A small number of randomized controlled trials (RCTs) in adults with mild to moderate asthma suggest that short-term statin treatment does not improve lung function or symptom control, except for a possible improvement in quality of life and symptoms in smokers with asthma. Several observation studies report that statin use in asthma is associated with a reduced risk of asthma-related emergency department visits, oral corticosteroid dispensing or hospital admissions. Statins treatment in asthma may have modest local anti-inflammatory effects in the airways. There is a need for a large RCT examining the effects of statins on reducing exacerbations, particularly in severe asthma. In COPD, observational studies suggest that statin use is associated with reduced morbidity and/or mortality, whereas a large RCT concluded that simvastatin did not reduce exacerbations in patients with COPD that had no cardiovascular indication for statin treatment. It is possible that a subgroup of COPD patients with cardiovascular indications for statins and/or systemic inflammation may obtain clinical benefit from statin treatment. Understanding the immunomodulatory effects of statins in asthma and COPD may lead to the development of novel targeted interventions.
Keywords: Anti-inflammatory, asthma, clinical trials, COPD, exacerbations, immunomodulation, statin.
Graphical Abstract
Current Molecular Pharmacology
Title:Clinical Studies of Statins in Asthma and COPD
Volume: 10
Author(s): Neil C. Thomson
Affiliation:
Keywords: Anti-inflammatory, asthma, clinical trials, COPD, exacerbations, immunomodulation, statin.
Abstract: Immunomodulatory effects of statins in vitro and in experimental models of asthma and COPD could potentially be relevant to the treatment of chronic airway diseases. This article provides an overview of the evidence from the key clinical studies on the effects of statins on clinical outcomes and inflammatory biomarkers in asthma and COPD. Future directions for clinical studies of statins in asthma and COPD are discussed. A small number of randomized controlled trials (RCTs) in adults with mild to moderate asthma suggest that short-term statin treatment does not improve lung function or symptom control, except for a possible improvement in quality of life and symptoms in smokers with asthma. Several observation studies report that statin use in asthma is associated with a reduced risk of asthma-related emergency department visits, oral corticosteroid dispensing or hospital admissions. Statins treatment in asthma may have modest local anti-inflammatory effects in the airways. There is a need for a large RCT examining the effects of statins on reducing exacerbations, particularly in severe asthma. In COPD, observational studies suggest that statin use is associated with reduced morbidity and/or mortality, whereas a large RCT concluded that simvastatin did not reduce exacerbations in patients with COPD that had no cardiovascular indication for statin treatment. It is possible that a subgroup of COPD patients with cardiovascular indications for statins and/or systemic inflammation may obtain clinical benefit from statin treatment. Understanding the immunomodulatory effects of statins in asthma and COPD may lead to the development of novel targeted interventions.
Export Options
About this article
Cite this article as:
Thomson C. Neil, Clinical Studies of Statins in Asthma and COPD, Current Molecular Pharmacology 2017; 10 (1) . https://dx.doi.org/10.2174/1874467209666160112125911
DOI https://dx.doi.org/10.2174/1874467209666160112125911 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chromones and their Derivatives as Radical Scavengers: A Remedy for Cell Impairment
Current Topics in Medicinal Chemistry Prospects of Developing Medicinal Therapeutic Strategies and Pharmaceutical Design for Effective Gluten Intolerance Treatment
Current Pharmaceutical Design Evaluation of the Anthelmentic Activity of Garlic (Allium sativum) in Mice Naturally Infected with Aspiculuris tetraptera
Recent Patents on Anti-Infective Drug Discovery Airway Smooth Muscle Phenotype and Function: Interactions with Current Asthma Therapies
Current Drug Targets The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Vascular Remodelling and Angiogenesis in Asthma: Morphological Aspects and Pharmacological Modulation
Inflammation & Allergy - Drug Targets (Discontinued) Eotaxin Receptor (CCR3) Antagonism in Asthma and Allergic Disease
Current Drug Targets - Inflammation & Allergy Editorial (Thematic Issue: Natural Products for the Attenuation of Allergic Airway Inflammation)
Current Pharmaceutical Design Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Current Medicinal Chemistry Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Extensive Phytochemistry, Comprehensive Traditional Uses, and Critical Pharmacological Profile of the Great Mullein: Verbascum thapsus L
The Natural Products Journal Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recombinant Proteins and Peptides as Diagnostic and Therapeutic Reagents for Arthropod Allergies
Protein & Peptide Letters Sensitization to Inhaled Allergens in Atopic Children in Jordan Capital, Amman: A Cross-sectional Study
Current Respiratory Medicine Reviews The Effects of Allergen and Anti-Allergic Drugs on Murine Hemopoietic Cells: Moving Targets, Unusual Mechanisms, and Changing Paradigms
Current Drug Targets - Inflammation & Allergy Give Boron a Chance: Boron Containing Compounds Reach Ionotropic and Metabotropic Transmembrane Receptors
Mini-Reviews in Medicinal Chemistry Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design